triple agonist glp 1 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide: How the Triple Agonist

Whilst their primary indication remains glycaemic control, emerging evidence suggests GLP-1 receptor agonists exert effects beyond glucose metabolism

[DOI] [PMC free article] [PubMed] [Google Scholar] 165.Castellana M., Cignarelli A., Brescia F., Perrini S., Natalicchio A., Laviola L., Giorgino F

In animal models of mania, liraglutide augmented the activity of the mood stabilizers sodium valproate 156 and lithium 157

2023), and efinopegdutide (Romero-Gmez et al

Sleep Dysfunction and Gastrointestinal Diseases

The FDA approved this drug for use in weight management in Research from 2023 has found that people taking Wegovy lost more weight than those taking a placebo, with a mean difference in total weight loss of Zepbound Zepbound received FDA approval for use in weight management in Saxenda Saxenda received While Saxenda is effective for weight loss, people may notice slower or less obvious results